ADCT Q3 2025 Earnings Call Summary

ADC Therapeutics Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

Net Product Revenues: $15.8 million for Q3 2025, down from $18 million in Q3 2024, reflecting stable ordering patterns.
Operating Expenses: Totaled $45 million (non-GAAP), a 12.1% decrease year-over-year, primarily due to lower R&D costs.
Net Loss: Reported at $41 million, or $0.30 per share, an improvement from a $44 million loss ($0.42 per share) in Q3 2024.
Cash Position: $234.7 million at the end of Q3, bolstered to approximately $292.3 million post a $60 million private placement in October, extending cash runway to at least 2028.

2. Strategic Updates and Business Highlights

ZENLATA: Focus remains on ZENLATA as a treatment for third-line plus DLBCL, with ongoing trials showing promising data.
- LOTUS Trials:
  - LOTUS V (Phase III) and LOTUS VII (Phase Ib) trials are progressing, with updates expected soon.
  - LOTUS V aims to combine ZENLATA with rituximab, while LOTUS VII combines it with glafitamab.
Indolent Lymphomas: Positive data from Phase II trials for ZENLATA in relapsed/refractory follicular lymphoma and marginal zone lymphoma.
Market Potential: ZENLATA is projected to achieve peak annual revenues of $600 million to $1 billion in the U.S. with potential expansions into earlier treatment lines.

3. Forward Guidance and Outlook

Upcoming Data Releases:
- LOTUS VII interim data expected by year-end 2025.
- Top-line results from LOTUS V anticipated in 2026, with regulatory submissions and potential approvals in 2027.
Revenue Growth: Anticipated revenue ramp-up post-approval and compendia inclusion, with expectations for significant growth in the first two years following these milestones.

4. Challenges and Points of Concern

Revenue Decline: Year-over-year revenue decrease raises concerns about market traction.
Competitive Landscape: Increased competition from bispecific therapies and other agents in the DLBCL and indolent lymphoma markets could impact ZENLATA's market share.
Enrollment Targets: While enrollment in trials has accelerated, there is uncertainty regarding timelines and the ability to meet patient targets.

5. Notable Q&A Insights

Enrollment Acceleration: Management confirmed that post-data release, enrollment in LOTUS VII has accelerated, but they are still targeting 100 patients without adjusting this target.
Revenue Inflection Points: Expected revenue growth following LOTUS V and LOTUS VII data releases and subsequent approvals, with a focus on the first half of 2027 for significant revenue ramp-up.
Market Positioning: Management clarified that ZENLATA's positioning in both academic and community settings is crucial, with a strategy to address both complex and broadly accessible therapy segments.

Overall, ADC Therapeutics is navigating a challenging landscape with stable revenues from ZENLATA, promising trial data, and a strengthened financial position, while also facing competitive pressures and the need for successful trial outcomes to drive future growth.

ADCT — ADC Therapeutics S.A.